Combatting Muscle Loss in Obese Adult Patients on GLP-1 Medications Through Dietary Counseling and Exercise During Treatment Evaluates Whether a 12-week Exercise and Individualized Nutrition Program Can Reduce Muscle and Bone Loss and Improve Strength, Fitness, and Function in Obese Adults on GLP-1

NCT07554417 on ClinicalTrials.gov · last registry update 2026-04-28

Registered but never opened — and the completion date on file, 29 June 2026, has already passed. Its estimated completion date, 29 June 2026, has passed with no update to the record. Primary outcome, as filed: Change in Skeletal Muscle Mass. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. semaglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status: NOT_YET_RECRUITING
Phase: P4
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: William Marsh Rice University
Sponsor type: Other
Enrollment: 20
Started: 2026-04-06
Primary completion: 2026-06-29 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in Skeletal Muscle Mass

Conditions studied

GLP - 1 · Obesity & Overweight · Muscle Loss · Exercise Intervention · Dietary Assessment

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.